Live
FierceBiotechAntibodies that stop measles from stabbing cells could become new treatments for the surging virus, study suggestsFierceBiotechBeOne shelves 5 cancer programs, halts phase 2 rheumatoid arthritis trialEndpoints NewsEntrada stock falls on Duchenne data; Wegovy expands accessCellVirological characteristics of SARS-CoV-2-related coronaviruses dynamically circulating in Southeast AsiaCellAffinity-matured B cell responses neutralizing type-I interferons underlie severe viral infectionsCellMulti-cohort proteogenomic analyses reveal genetic effects across the proteome and diseasomeFierceBiotechBlackstone invests $250M in Anagram to reduce burden of cystic fibrosis complicationFierceBiotechFDA to reconsider shock rejection of cell therapy Ebvallo. Could uniQure be next?BioWorldFirst measles treatment advances as vaccination rates dropFierceBiotechAscendis axes IL-2 program in retreat from oncology expansionPharmaVoiceNovo hikes guidance on Wegovy pill’s fast sales startEndpoints NewsAmgen adds $300M to Puerto Rico budget; Novartis to exit oral drug factory in Germany

Archiv

Aktuell Älteste Löschen
@Agilent
Gesamt 513
Quelle Agilent
Suche --